A detailed history of State Street Corp transactions in Immunic, Inc. stock. As of the latest transaction made, State Street Corp holds 155,503 shares of IMUX stock, worth $183,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,503
Previous 130,503 19.16%
Holding current value
$183,493
Previous $172,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.98 - $1.44 $24,500 - $36,000
25,000 Added 19.16%
155,503 $172,000
Q1 2024

May 15, 2024

BUY
$1.14 - $1.53 $5,357 - $7,191
4,700 Added 3.74%
130,503 $172,000
Q1 2023

May 15, 2023

BUY
$1.35 - $2.87 $65,610 - $139,482
48,600 Added 62.95%
125,803 $187,000
Q4 2022

Feb 14, 2023

BUY
$1.13 - $10.8 $12,768 - $122,040
11,300 Added 17.15%
77,203 $108,000
Q2 2022

Aug 15, 2022

SELL
$3.13 - $12.25 $793,993 - $3.11 Million
-253,672 Reduced 79.38%
65,903 $229,000
Q1 2022

May 16, 2022

SELL
$9.54 - $14.26 $1.38 Million - $2.06 Million
-144,425 Reduced 31.13%
319,575 $3.61 Million
Q4 2021

Feb 14, 2022

BUY
$7.34 - $10.25 $169,231 - $236,324
23,056 Added 5.23%
464,000 $4.44 Million
Q3 2021

Nov 15, 2021

BUY
$8.05 - $13.29 $721,666 - $1.19 Million
89,648 Added 25.52%
440,944 $3.9 Million
Q2 2021

Aug 16, 2021

BUY
$11.76 - $16.85 $1.2 Million - $1.72 Million
102,277 Added 41.07%
351,296 $4.31 Million
Q1 2021

May 17, 2021

BUY
$14.21 - $25.3 $2.31 Million - $4.12 Million
162,719 Added 188.55%
249,019 $3.97 Million
Q4 2020

Feb 16, 2021

BUY
$14.8 - $20.37 $231,990 - $319,299
15,675 Added 22.19%
86,300 $1.32 Million
Q3 2020

Nov 10, 2020

BUY
$11.74 - $22.0 $437,491 - $819,830
37,265 Added 111.71%
70,625 $1.31 Million
Q2 2020

Aug 14, 2020

BUY
$5.67 - $15.86 $189,151 - $529,089
33,360 New
33,360 $404,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $36.1M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.